Phospho-PTEN (Ser380/Thr382/383) (Clone: E4) rabbit mAb SureLight488 conjugate

PTEN has been identified as a tumor suppressor gene and has been found to be mutated in a significant number of human cancers, including prostate, brain, and breast cancer. PTEN shares sequence homology with the protein-tyrosine phosphatase (PTPase) family of proteins and negatively regulates the PI3K/Akt pathway. PTEN de-phosphorylates target proteins, and recombinant PTEN has been shown to have phosphoinositide 3-phosphhatase and inositol phosphate 3-phosphatase activity. Studies of primary tumor cells show a loss of PTEN expression after metastasis to the brain, via astrocyte-derived microRNAs. A cluster of phosphorylation sites (S380, T382, T383, and S385) in the C-terminal tail of PTEN drive a conformational change that reduces PTEN activity by inhibiting membrane interactions.

Product Specifications

Product Name Alternative

Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase, Mutated in multiple advanced cancers 1, MMAC1, Phosphatase and tensin homolog, TEP1

Host

Rabbit

Reactivity

Human, Mouse

Immunogen

A synthetic phospho-peptide corresponding to residues surrounding Ser380 and Thr382/383 of human phospho PTEN

Clonality

Monoclonal

Clone

PTENS380T382383-E4

Applications

FACS

Format

Conjugated

Components

1X PBS, 0.09% NaN3, 0.2% BSA

Storage Conditions

Store at 2-8°C. Avoid repeated freeze and thaw cycles.

Applications Notes

For flow cytometric staining, the suggested use of this reagent is 5 μL per million cells or 5 μL per 100 μL of staining volume. It is recommended that the reagent be titrated for optimal performance for each application.